Key Highlights
- Neuphoria Therapeutics shares closed up 18% at $3.92.
- Neuphoria and Scancell Holdings (AIM: SCLP) finalized an all-stock merger agreement.
- Scancell will take over Neuphoria to form a unified company trading on Nasdaq under the symbol SCLT.
- The combined company will maintain its AIM presence.
Neuphoria Therapeutics (NASDAQ: NEUP) shares closed up 18% at $3.92 after the company and Scancell Holdings plc (AIM: SCLP) finalized an agreement for an all-stock merger, one of the more significant corporate actions among the disclosed biopharma names this session.
What Happened
Scancell will take over Neuphoria to form a unified company trading on the Nasdaq under the symbol SCLT while maintaining its AIM presence, a structure that gives the combined entity a dual-listing profile spanning both U.S. and U.K. capital markets.
All-stock mergers of this kind typically allow the combined company to preserve cash on hand rather than funding a transaction through a cash payout, a structural feature that can be particularly valuable for clinical-stage biotech companies that need to conserve capital for ongoing research and development.
Market Reaction
Shares rose 18% following the finalized merger agreement, reflecting investor response to the combination and the resulting dual-listed structure spanning Nasdaq and AIM.
The positive share price reaction suggests investors view the combination of Neuphoria's and Scancell's respective pipelines and cash positions as additive, though the disclosed information does not specify which company's therapeutic programs will take priority within the combined entity.
Maintaining a presence on both Nasdaq and AIM under the new SCLT ticker could broaden the combined company's access to both U.S. and U.K. institutional investor bases, a potential structural benefit that may have also contributed to the positive market response.
For shareholders of both legacy companies, an all-stock merger of this kind means their ownership stake converts into shares of the newly combined entity rather than being cashed out, aligning their financial outcome directly with the combined company's future performance under the SCLT ticker.
Outlook
The disclosed information does not include a specific closing timeline for the merger; investors are likely to watch for further detail on the combined company's operations, leadership structure, and pipeline prioritization under the new SCLT ticker.
As with most biotech mergers, the durability of today's share price gain is likely to depend on how effectively the combined company communicates its near-term clinical and financial priorities once the transaction is finalized and trading begins under the new symbol.
Dual-listed biotech companies of this kind often face the added complexity of coordinating disclosure and governance requirements across two separate regulatory regimes, in this case Nasdaq's U.S. listing rules and the London Stock Exchange's AIM market rules. How smoothly the combined Neuphoria-Scancell entity navigates that dual-listing structure is likely to be an early test of the merger's operational execution.
What merger did Neuphoria Therapeutics finalize?
An all-stock merger agreement with Scancell Holdings plc, with Scancell taking over Neuphoria.
What will the combined company be called and where will it trade?
The unified company will trade on Nasdaq under the symbol SCLT while maintaining its AIM presence.
Why did Neuphoria shares rise 18%?
Shares rose following the finalized merger agreement with Scancell Holdings.






Please wait processing your request...